EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IGFBP3 As a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma: A Multi‐Cohort Analysis

Yin Tao iD, Yunji Xu, Xupeng Chen, Yali Zhou, Jingli Fu

Journal of Clinical Laboratory Analysis · 2026-07 · 40 (13)

DOI: 10.1002/jcla.70265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 06.07.2026. Verfasst von Yin Tao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Zhuzhou Central Hospital, Zhuzhou, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Insulin-Like Growth Factor Binding Protein 3, Biomarkers, Tumor. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Project of Health Commission of Hunan Province, Hunan Provincial Natural Science Foundation, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to investigate the expression patterns and prognostic significance of insulin‐like growth factor‐binding protein 3 ( IGFBP3 ) in hepatocellular carcinoma (HCC) and other cancer types.

Methods

IGFBP3 expression was analyzed using The Cancer Genome Atlas (TCGA)‐LIHC, International Cancer Genome Consortium (ICGC‐LIRI‐JP), Gene Expression Omnibus (GEO; GSE102079 and GSE112790), and Genotype‐Tissue Expression (GTEx) databases. Experimental validation included immunohistochemistry (IHC) and quantitative real‐time PCR (qRT‐PCR) on 10 paired HCC tissues. Survival was assessed via Kaplan–Meier analysis in TCGA, ICGC, and 47‐patient cohorts stratified by IGFBP3 immunoreactive score (IRS). Univariate and multivariate Cox regression identified prognostic factors. Immune infiltration correlations were evaluated using ESTIMATE and TIMER algorithms, with pan‐cancer analysis conducted via TCGA database.

Results

IGFBP3 was significantly downregulated in HCC across all cohorts and validated in our cohort ( p < 0.01). Elevated intratumoral IGFBP3 correlated with advanced tumor stage, high grade, and elevated AFP. High IGFBP3 predicted poorer overall survival in TCGA (HR = 1.666, p = 0.004) and ICGC (HR = 4.631, p = 0.0009), and was associated with shorter survival in our cohort ( p = 0.0002). Multivariate analysis confirmed IGFBP3 as an independent prognostic factor (HR = 2.95, p = 0.014). IGFBP3 expression positively correlated with immunosuppressive cell infiltration (M2 macrophages, regulatory T cells) and enriched pathways including TGF‐β and JAK–STAT signaling. Pan‐cancer analysis revealed cancer‐specific expression patterns, with HCC showing both overall downregulation and high‐risk prognostic value in high‐expression tumors.

Conclusion

IGFBP3 was low expression in HCC, yet high expression indicates poor prognosis. This suggests that IGFBP3 is a potential novel prognostic biomarker and therapeutic target in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsInsulin-Like Growth Factor Binding Protein 3Biomarkers, TumorHumansFemaleMalePrognosisGene Expression Regulation, NeoplasticMiddle AgedCohort StudiesKaplan-Meier EstimateAged

Stichwörter der Autor:innen

IGFBP3biomarkerhepatocellular carcinomaimmune infiltrationprognosis

Substanzen

Insulin-Like Growth Factor Binding Protein 3Biomarkers, TumorIGFBP3 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Department of General Surgery, The Second Affiliated Hospital, Hengyang Medical College, University of South China, Hengyang, Hunan, China.
  • Department of Clinical Laboratory, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Department of Neonatology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.
  • Department of Infectious Diseases, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.

ORCID-Profile: Yin Tao

Förderung

  • Health Research Project of Health Commission of Hunan Province
  • Hunan Provincial Natural Science Foundation
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Tao, Y., Xu, Y., Chen, X., Zhou, Y., & Fu, J. (2026). IGFBP3 As a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma: A Multi‐Cohort Analysis. Journal of Clinical Laboratory Analysis, 40(13). https://doi.org/10.1002/jcla.70265

Vancouver

Tao Y, Xu Y, Chen X, Zhou Y, Fu J. IGFBP3 As a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma: A Multi‐Cohort Analysis. Journal of Clinical Laboratory Analysis. 2026;40(13). doi:10.1002/jcla.70265

BibTeX
@article{Tao2026,
  author = {Tao, Yin and Xu, Yunji and Chen, Xupeng and Zhou, Yali and Fu, Jingli},
  title = {IGFBP3 As a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma: A Multi‐Cohort Analysis},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2026},
  volume = {40},
  number = {13},
  doi = {10.1002/jcla.70265}
}
Kostenlos starten →